Finkelstein 1999.

Study characteristics
Methods	Trial design: Randomised controlled trial
Participants	Participants: 38 women were randomised and analysed. Mean age: Group 1: 34 ± 7 years, group 2: 34 ± 7 years Inclusion criteria: Symptomatic, laparoscopically proven endometriosis  Participated in the original study Ovulation was confirmed by a luteal phase serum progesterone level greater than 5 ng/dL (19, 20).  Normal serum calcium, inorganic phosphate, alkaline phosphatase, bilirubin, creatinine, free T4 index, and PRL concentrations Exclusion criteria:  Women with disorders or taking medications known to affect bone metabolism Women who received a therapy or who developed a medical condition known to affect BMD during the year after active therapy Setting: United States of America Timing: not stated
Interventions	Nafarelin acetate (Synarel, Syntex Laboratories, Inc., Palo Alto, CA; 200 mg, intranasally, twice daily) (group 1; n  = 28)  versus Nafarelin acetate plus human PTH [40 mg (500 U), sc, daily] for 6–12 months (group 2; n =  23)
Outcomes	Changes in BMD and bone turnover Biochemical markers of bone turnover
Notes	Intention‐to‐treat analysis: not stated Sample size calculation: not stated Funding: This work was supported by NIH Grants R29‐DK‐43341 and RR1066 and a NIH Clinical Associate Physician Award (to J.S.F.).
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The women were randomly assigned using computer generated cards.
Allocation concealment (selection bias)	Unclear risk	No details of method used to conceal allocation were provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details provided of blinding of participants or personnel
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided of blinding of outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	No losses to follow‐up
Selective reporting (reporting bias)	Low risk	The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified.
Other bias	Low risk	No other risk of bias detected